Publication Name	World Journal of Gastroenterology
Manuscript ID	101292
Country	Australia

Received	2024-09-12 12:46
Peer-Review Started	2024-09-12 12:46
To Make the First Decision
Return for Revision	2024-10-15 21:34
Revised	2024-10-22 04:43
Second Decision	2024-11-18 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-11-18 05:41
Articles in Press	2024-11-18 05:41
Publication Fee Transferred	2024-11-20 01:28
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-12-05 00:28
Publish the Manuscript Online	2024-12-18 07:36

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Prospective Study
Article Title	Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study
Manuscript Source	Unsolicited Manuscript
All Author List	Thanaboon Chaemsupaphan, Aviv Pudipeddi, Hui-Yu Lin, Sudarshan Paramsothy, Viraj C Kariyawasam, Melissa Kermeen and Rupert W Leong
ORCID	Author(s) ORCID Number Thanaboon Chaemsupaphan http://orcid.org/0009-0001-3408-7277 Aviv Pudipeddi http://orcid.org/0000-0002-3664-2246 Sudarshan Paramsothy http://orcid.org/0000-0002-9097-6028 Viraj C Kariyawasam http://orcid.org/0000-0003-2623-1336 Rupert W Leong http://orcid.org/0001-0009-3242-3933
Funding Agency and Grant Number	Funding Agency Grant Number Takeda Australia IISR-2016-101883
Corresponding Author	Rupert W Leong, MD, Professor, Department of Gastroenterology and Liver Services, Concord Repatriation General Hospital, Hospital Road, Sydney 2139, New South Wales, Australia. rupert.leong@health.nsw.gov.au
Key Words	Pharmacokinetic; Vedolizumab; Thiopurine; Ulcerative colitis; Trough concentration; Antibody; Inflammatory bowel diseases
Core Tip	This prospective study investigated the pharmacokinetic relationship between vedolizumab trough concentrations and clinical outcomes in ulcerative colitis patients who had achieved clinical remission, on vedolizumab with or without thiopurine. Vedolizumab levels remained stable over 48 weeks, regardless of thiopurine withdrawal. Significant associations between vedolizumab trough concentrations and endoscopic, histologic, and histo-endoscopic remission at week 48 suggest that monitoring vedolizumab levels could be beneficial, with a threshold of > 11.3 µg/mL linked to sustained clinical remission. Although thiopurine withdrawal did not affect vedolizumab levels, it may necessitate higher vedolizumab trough concentrations to maintain remission.
Publish Date	2024-12-18 07:36
Citation	<p>Chaemsupaphan T, Pudipeddi A, Lin HY, Paramsothy S, Kariyawasam VC, Kermeen M, Leong RW. Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study. <i>World J Gastroenterol</i> 2025; 31(2): 101292</p>
URL	https://www.wjgnet.com/1007-9327/full/v31/i2/101292.htm
DOI	https://dx.doi.org/10.3748/wjg.v31.i2.101292

Full Article (PDF)	WJG-31-101292-with-cover.pdf
CONSORT 2010 Statement	101292-CONSORT-2010-statement.pdf
Manuscript File	101292_Auto_Edited_062029.docx
Answering Reviewers	101292-answering-reviewers.pdf
Audio Core Tip	101292-audio.mp3
Biostatistics Review Certificate	101292-biostatistics-statement.pdf
Clinical Trial Registration Statement	101292-clinical-trial-registration-statement.pdf
Conflict-of-Interest Disclosure Form	101292-conflict-of-interest-statement.pdf
Copyright License Agreement	101292-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	101292-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	101292-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	101292-institutional-review-board-statement.pdf
Peer-review Report	101292-peer-reviews.pdf
Scientific Misconduct Check	101292-scientific-misconduct-check.png
Scientific Editor Work List	101292-scientific-editor-work-list.pdf
CrossCheck Report	101292-crosscheck-report.pdf